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A Critical Look at the Role of Chemotherapy in Older
Patients with Non-small Cell Lung Cancer
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Lung cancer remains the leading cause of cancer-related death in the
United States, and, at the same time, the American population is
getting older. These two factors have given rise to a greater focus on
how best to treat non-small cell lung cancer in older patients with
cancer. Recent studies have defined the benefits of chemotherapy in
older patients with metastatic cancer, and the use of single agent
therapy is well justified. In this review, we focus on the need to
initiate clinical trials that are specifically designed for older
patients with cancer, the role ongoing efforts to identify prog-
nostic factors, the importance of studying newer agents up front
in older patients, and the value of phase III trials in this patient
population.
(J Thorac Oncol. 2007;2: 83–90)
Medical oncologists are seeing more geriatric patientswith lung cancer than they were just a few years ago.
Two factors explain this phenomenon. First, lung cancer
continues to be the most common cause of cancer-related
death in the United States, and recent demographic estimates
highlight this statistic. It is estimated that 174,470 patients
will be diagnosed with lung cancer in the upcoming year and
that 162,460 patients will die from it.1 These large numbers,
coupled with their almost near equivalence, point to the
negative impact of this disease in the United States. Second,
the American population is aging. Today the median patient
age at the time of diagnosis of non-small cell lung cancer is
68 years.2 In a recent publication titled “Annual report to the
Nation on the Status of Cancer, 1973 to 1999, Featuring
Implications of Age and Aging on US Cancer Burden,”
Edwards et al.3 predicted that by 2050, the number of newly
diagnosed patients with lung cancer aged 85 years or older
will have quadrupled. Thus, the collision of these two demo-
graphic factors—high rates of lung cancer coupled with an
aging American population—gives rise to the rapidly emerg-
ing challenge of how best to treat older patients with non-
small cell lung cancer. Today, medical oncologists are grap-
pling with the problem of lung cancer in older patients more
than ever before, and they will likely continue to do so in
years to come.
PITFALLS IN RELYING EXCLUSIVELY ON
CURRENT DATA
If we re-analyze clinical trial data accumulated through
the years, we gain a preliminary understanding of how to treat
older patients with lung cancer. As a result of this approach,
a large body of literature has been generated. This literature
suggests that older patients with cancer do almost as well as
their younger counterparts when treated with conventional
cancer therapy. Major cooperative groups in North America,
such as the Eastern Cooperative Oncology Group (ECOG),
the Cancer and Leukemia Group B (CALGB), the Southwest
Oncology Group (SWOG), the National Cancer Institute of
Canada (NCIC), and the North Central Cancer Treatment
Group (NCCTG), have re-analyzed prospectively gathered
data to investigate the prognostic and predictive effects of
age. These efforts provide an important starting point to begin
understanding how best to provide cancer therapy to older
patients.
As one such example, the ECOG presented their pre-
liminary findings of a re-analysis of ECOG 1594, a 1139-
patient landmark clinical trial that was originally conducted
to determine the optimal chemotherapy regimen for patients
with metastatic non-small cell lung cancer.4,5 Patients were
randomly assigned to one of four platinum-based study arms
as first-line therapy. Of these patients, 227 were aged 70 years
or older. This re-analysis focused on differences in outcome
between these older patients and the remaining 912 younger
patients. Older patients had a greater number of cardiovascu-
lar morbidities (p 0.00001) and non-cardiorespiratory mor-
bidities (p  0.008) at study entry. However, when outcomes
were analyzed from the standpoint of whether patients com-
pleted a total of six cycles of chemotherapy and whether they
suffered adverse events of grade 4 or worse, there were no
statistically significant differences between older and younger
patients. Moreover, 1- and 2-year overall survival rates were
not statistically different between older and younger patients.
In short, this re-analysis of a landmark study on the treatment
of metastatic non-small cell lung cancer suggests comparable
outcomes based on age.
A second example of such a re-analysis that found
comparable clinical outcomes based on age is found in
CALGB 9730.6 The primary end point of this study as
originally stated was to determine the efficacy of paclitaxel
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alone versus the combination of paclitaxel and carboplatin
among patients with metastatic non-small cell lung cancer.
Interestingly, a relevant subset analysis had been planned a
priori with the goal of evaluating this same question among
patients older than 70 years at the time of enrollment. This
subset analysis among older patients revealed lower response
rates with single-agent as opposed to combination therapy in
older patients: 17% versus 30%. In addition, failure-free
survival was significantly shorter: 2.5 months (95% confi-
dence interval, 2.3–2.8 months) and 4.6 months (95% confi-
dence interval, 4.1–5.3 months), respectively. However, the
1-year survival rate with single-agent therapy (n  78) was
31% versus 35% with combination therapy (n  77), a
difference that was not statistically significant. Based on
comparable findings among the younger cohort, these inves-
tigators concluded, “The treatment arm difference observed
among older patients was similar to that observed among
younger patients.” Of note, within this trial as a whole, im-
proved tumor response rate and failure-free survival did not
translate to improvements in overall survival, and the same
scenario clearly occurred among the older patients. Thus, al-
though this study did not demonstrate the survival advantage
that one might have expected to see with combination chemo-
therapy, the comparability of outcomes between older and
younger patients is once again a noteworthy finding.
A relevant question that often arises in the treatment of
patients with metastatic non-small cell lung cancer is whether
they can tolerate cisplatin-based chemotherapy. Langer et al.7
re-analyzed ECOG 5592 and observed that they can. The orig-
inal study design represented a randomized phase III trial that
tested cisplatin plus etoposide versus cisoplatin plus paclitaxel
along with growth factor support versus a lower dose of cisplatin
plus paclitaxel. Eighty-six patients (15%) were 70 years of age
or older, and the other 488 patients were younger. Adverse
events from chemotherapy were more frequently observed in
older patients; specifically, higher rates of neutropenia (p 
0.001), neuropsychiatric toxicity (p  0.002), and weight loss
(p  0.006) were observed among older patients based in
gender-related subanalyses. Tumor response rate, other adverse
event rates, and survival were otherwise equivalent between
groups. The investigators acknowledge that likely only the “fit”
elderly were enrolled in this trial, but they also concluded that
“advanced age alone should not preclude appropriate non-small
cell lung treatment.” 7
A fourth example of this type of retrospective re-
analysis based on age consists of a small, preliminary report
that focused on patients who have metastatic non-small cell
lung cancer and who are 80 years of age or older. This report
merits mention because few studies have focused on octoge-
narians. Hesketh et al.8 re-analyzed data from two different
cooperative group trials: SWOG 0027, which included 23
patients in this older age range, and LUN 6, which included
26 such patients. Comparisons were made to the remainder of
the cohort, which consisted of 94 younger patients. It is
important to point out that the “younger” patients in this
cohort were actually not that young: all were 70 years of age
or older, but none qualified as octogenarians at study entry.
Patients who participated in these two trials received either
vinorelbine and docetaxel or docetaxel alone. These investi-
gators found that among patients with a performance score of
1 or better, octogenarians seemed to live as long as younger
patients in their seventies with only a slight trend of better
survival among younger patients (median survival 11 months
and 7 months among younger and older patients, respectively
[p  0.2]). Among patients with a performance status of 2,
comparable survival was observed between groups. Adverse
event profiles were comparable based on age. Again, al-
though this study is small, its focus on octogenarians makes
it an important study. Its findings suggest that even among
very old patients with cancer, comparable outcomes are
observed.
Yet a fifth example of this type of analysis of the
elderly focused on patients with locally advanced non-small
cell lung cancer. The NCCTG re-examined one of its com-
bined modality therapy trials of patients with locally ad-
vanced non-small cell lung cancer.9 All 246 patients who had
participated in the original age-unspecified trial had received
etoposide and cisplatin along with radiation. Of the patients
in this cohort, 63 (26%) were 70 years of age or older. When
data were re-analyzed on the basis of age (70 years of age or
older versus younger patients), it seemed that survival was
comparable between both groups, with 2-year survival rates
of 36% and 39%, respectively. The main difference between
the age-defined cohorts centered on adverse events. Rates of
grade 4 or worse adverse events, which included hematologic
toxicity and pneumonitis, were higher in older patients com-
pared with younger patients: 81% and 62%, respectively (p
0.007). Again, the same conclusion emerged: older patients
receive just as much benefit from chemotherapy as their
younger counterparts in exchange for perhaps somewhat
higher and more severe rates of adverse events.
What about adjuvant chemotherapy for geriatric pa-
tients with non-small cell lung cancer? Using this same
approach of re-analyzing prospectively gathered data, Pepe et
al.10 provided preliminary data on a re-analysis of their
adjuvant chemotherapy trial JBR10 to answer this question.
The primary aim of this trial was to assess the difference in
survival among patients with resected stage IB and II non-
small cell lung cancer after either chemotherapy with vinorel-
bine and cisplatin versus no chemotherapy. As originally
reported, this study did demonstrate that chemotherapy led to
a survival advantage within the entire cohort. In specifically
addressing whether older patients with non-small cell lung
cancer should be offered adjuvant chemotherapy, Pepe et al.
focused on patients who were 65 years of age or younger
versus patients who were older than 65 years. The latter
group consisted of 155 patients. Survival by age demon-
strated a trend that favored younger patients (hazard ratio,
0.75; 95% confidence intervals, 0.58–1.04). Of greater rele-
vance, the overall survival of patients who were older than 65
years old was improved with chemotherapy (hazard ratio,
0.61; 95% confidence intervals, 0.38–0.98). Of note, this
survival advantage occurred even though fewer older patients
completed the full course of chemotherapy. The investigators
cautioned that only a few patients 75 years of age partici-
pated in this adjuvant study and that further study of adjuvant
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therapy in patients in this much older age group is warranted.
Nonetheless, their conclusion was that adjuvant chemother-
apy should not be withheld on the basis of age alone.
Is this conclusion of parity of outcomes between the
young and old final? We argue that it might not be. First, it is
important to point out that clinical trial participation among
patients with cancer tends to be low in the United States, but
enrollment of geriatric patients with cancer is particularly
low: fewer than 3% of older patients with cancer are enrolled
in clinical trials sponsored by the National Cancer Institute.11
Even if one acknowledges that clinical trial participation is
suboptimal across all age groups in the United States, and if
one instead looks for comparable representation across age
groups, such comparable representation is not observed. The
SWOG published a study showing that only 39% of patients
with lung cancer enrolled in SWOG clinical trials between
1993 and 1996 were older than 65 years of age. During this
same period, however, 66% of the general population with
cancer fell within this older age group.12 These statistics point
to a discrepancy between the percentage of older patients in
clinical trials and the percentage of older patients in the
general population. Any conclusions we draw about cancer
therapy in older patients based on such retrospective re-
analyses may be biased by lack of adequate representation of
the elderly.
Second, it is important to scrutinize the thoughtful
decision-making that transpires in the oncologist’s office. If a
clinical trial is designed with younger patients in mind, it is
unlikely that an oncologist will be willing to enroll, for
example, an 85-year-old, “frail” patient with non-small cell
lung cancer. Clinical judgment and experience may well lead
this oncologist to conclude that this frail 85-year-old may
acquire few benefits and suffer undue side effects. Thus, it is
likely that when these age-based retrospective analyses of
prospectively gathered data suggest that younger and older
patients fare the same with chemotherapy, this conclusion is
based on a fit group of older patients with cancer who were
appropriate candidates for a trial designed for younger pa-
tients. Such analyses make many assumptions that may, in
fact, widely propagate a tentative conclusion that patients
with cancer fare the same with cancer therapy regardless of
age. Although these analyses constitute a good starting point
from which to begin understanding cancer treatment in the
elderly, they also underscore the importance of gathering
prospective data that specifically focus on geriatric patients
with cancer with the intention of testing a priori hypotheses.
DEFINING THE ROLE OF CHEMOTHERAPY IN
THIS AGE GROUP
If we rely on trials that were specifically designed for
older patients with cancer, valuable information can be gleaned.
The fundamental question of whether chemotherapy should be
offered to older patients has been answered by such a trial. The
Elderly Lung Cancer Vinorelbine Study Group (ELVIS) pub-
lished a phase III trial evaluating vinorelbine versus supportive
care alone in patients70 years old, and this trial demonstrated
a survival advantage with drug therapy.13 Among 161 lung
patients with cancer who were70 years of age, chemotherapy-
treated patients lived longer (median survival, 28 versus 21
weeks for vinorelbine-treated versus supportive care patients;
p 0.03) (Figure 1). Chemotherapy-treated patients also scored
better in terms of quality of life. However, because poor accrual
resulted in the study’s early closure, and because the primary
end point of this trial was quality of life—not survival—the
investigators urged caution in the interpretation of results. None-
theless, this study advances the argument that vinorelbine dem-
onstrates efficacy in the treatment of patients70 years old with
metastatic non-small cell lung cancer. More importantly, these
preliminary data support the role of chemotherapy for treating
older patients with metastatic non-small cell lung cancer. Be-
cause this trial was closed because of poor accrual and because
other trials have been slow to accrue with a “best supportive
care” arm, there will likely never again be a comparative trial of
this nature conducted with this intent. Thus, these preliminary
data may be the best and only data we will ever have on whether
chemotherapy is better than best supportive care in older patients
with non-small cell lung cancer with metastatic disease.
The findings of the ELVIS trial spawn yet another
question. Which is better for older patients with non-small
cell lung cancer: single-agent chemotherapy or multi-agent
therapy? Although the latter is well accepted among younger
patients with cancer, it can be disconcerting for some oncolo-
gists to prescribe it to some older patients with cancer who
remain candidates for chemotherapy. The decision to try
multi-agent therapy requires the oncologist to proceed with a
thoughtful and careful assessment of the patient before mak-
ing a final decision. However, if this assessment culminates in
a decision to offer single-agent chemotherapy, that approach
can be justified in the context of previous clinical trial data.
FIGURE 1. The Elderly Lung Cancer Vinorelbine Study
Group (ELVIS) trial compared vinorelbine versus best sup-
portive care among older patients with metastatic non-small
cell lung cancer and provided data to suggest that chemo-
therapy can prolong life in patients of this age group. (From:
Jatol A, Hillman S, Stella P, Green E, Adjel A, Nair S, Perez E,
Amin B, Schild SE, Castillo R, Jett JR; North Central Cancer
Treatment Group. Should elderly non-small-cell lung cancer
patients be offered elderly-specific trials? Results of a pooled
analysis from the North Central Cancer Treatment Group.
J Clin Oncol 2005;23(36):9113–9119. Reprinted with permis-
sion from the American Society of Clinical Oncology.)
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The Multicenter Italian Lung Cancer in the Elderly Study
(MILES) reported that either single-agent vinorelbine or
single-agent gemcitabine was equivalent to the combination
of both drugs in patients with cancer aged 70 years or older.14
This 698-patient trial examined several clinical end points,
such as survival, tumor response rate, and time-to-tumor
progression, and quality of life and concluded that single-
agent therapy was equivalent to combination therapy based
on all these end points, including the primary end point of
survival. Median survival rates (95% confidence intervals) in
the single-agent vinorelbine, single-agent gemcitabine, and
combination therapy arms were 36 weeks (30–45 weeks), 28
weeks (25–34 weeks), and 30 weeks (27–36 weeks), respec-
tively (Figure 2). These data indicate that single-agent ther-
apy is a viable option for older patients with non-small cell
lung cancer.
In fact, the adverse event data of this trial demonstrated
that single-agent therapy is in some ways preferable to
combination therapy. When combination therapy was com-
pared with single-agent vinorelbine, the latter seemed to yield
a more favorable adverse event profile with significantly less
severe and less frequent thrombocytopenia and significantly
less severe and less frequent hepatic toxicity. Similarly,
adverse events were less severe and less frequent with single-
agent gemcitabine compared with combination therapy when
anemia, neutropenia, nausea/vomiting, fatigue, extravasation,
cardiac events, and constipation were assessed. Again, single-
agent therapy can be justified.
Along these same lines, preliminary data from Takeda
et al.15 suggest that docetaxel may provide some benefits
compared with vinorelbine. These investigators conducted a
182-patient trial in which patients with stage IIIB and IV
non-small cell lung cancer who were 70 years of age or older
were randomly assigned to receive vinorelbine 25 mg/m2 on
days 1 and 8 of a 21-day cycle versus docetaxel 60 mg/m2/
day on day 1 of a 21-day cycle. Although the primary end
point of overall survival was not statistically different be-
tween the two groups, there seemed to be a trend in favor of
the docetaxel, with a median survival rate of 14.3 versus 9.9
months in docetaxel- versus vinorelbine-treated patients, re-
spectively (p  0.14). At the same time, progression-free
survival was more favorable among docetaxel-treated pa-
tients: 5.4 versus 3.1 months, respectively (p  0.001).
Tumor response rates also favored the docetaxel-treated
group, with the overall response rate of 22.7% versus 9.9%,
respectively (p  0.019). These data are only preliminary,
and the primary survival end point had not been met at the
time of this referenced report. Nonetheless, these data make
the point that single-agent therapy options require further
clarification and definition for older patients with cancer.
Particularly, as newer cancer drugs are emerging, there may
be a role for studying them as single agents in older patients
with cancer.
Along these lines, Jackman et al.16 described results of
a phase II study that examined 58 patients who were 70 years
of age or older and who had metastatic non-small cell lung
FIGURE 2. The Multicenter Italian Lung Cancer in the Elderly Study (MILES) trial tested single-agent versus combination ther-
apy among older patients with non-small cell lung cancer and provided clear justification for using single-agent therapy in
older lung patients with cancer who do not seem able to tolerate combination therapy. (From: Effects of vinorelbine on qual-
ity of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian
Study Group. J Natl Cancer Inst 1999;91(1):66–72. Reprinted with permission of the Oxford University Press.)
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cancer. These patients were treated with erlotinib 150 mg
orally once a day. Rash and diarrhea were common side
effects, as expected, but the treatment was otherwise well
tolerated. There were eight patients who manifested a re-
sponse within the cohort, and there were 32 patients with
stable disease. The median survival was 11 months. These
promising preliminary data suggest that, over time, less toxic
therapy will become increasingly available for the treatment
of older patients with lung cancer.
It is important to point out that, whereas prescribing
single-agent therapy can be justified in geriatric patients with
cancer, and whereas single-agent therapy has been cited as a
reasonable treatment option by the American Society of
Clinical Oncology,17 this approach does not constitute an
unbreakable rule. For example, Comella et al.18 conducted a
264 patient-study that included patients older than 70 years
and younger patients with a poor performance status. Patients
were randomly assigned to one of four treatment arms: 1)
gemcitabine 1200 mg/m2 intravenously on days 1 and 8 every
21 days; 2) paclitaxel 100 mg/m2 intravenously on days 1, 8,
and 15 every 28 days; 3) gemcitabine 1000 mg/m2 in com-
bination with paclitaxel 80 mg/m2 intravenously on days 1
and 8 every 21 days; or 4) gemcitabine 1000 mg/m2 in
combination with vinorelbine 25 mg/m2 intravenously on
days 1 and 8 every 21 days. Favorable median survivals of
slightly longer than 9 months were observed in the combina-
tion therapy arms, as opposed to 4 months with single-agent
therapy. At the same time, the doublet drug combinations
yielded no greater toxicity than the single agents. This study
is relatively small, but it nonetheless raises the possibility
that, for some older patients with cancer who seem to be in
otherwise good health with a favorable performance score,
combination therapy may be a reasonable option that might
lead to improved outcomes.
How might we integrate the results of all the foregoing
studies and formulate treatment recommendations for man-
aging older patients with lung cancer? Taken together, these
studies suggest that age alone is at best a crude predictor of
clinical outcomes and that clinical judgment must play a role
in determining how best to administer chemotherapy. Based
on robust data, single-agent chemotherapy can be justified in
older patients with non-small cell lung cancer, and organiza-
tions, such as the American Society of Clinical Oncology,
have endorsed this approach.17 At the same time, a large
number of studies—albeit sometimes biased as a result of
re-analyses of prospectively gathered data from age-unspec-
ified trials—make the point that the use of single-agent
chemotherapy is not mandatory and that some older patients
with cancer are able to tolerate and derive benefit from
multi-agent chemotherapy. Practicing oncologists can invoke
clinical trial justification for the use of either single-agent or
combination therapy to lend credence to the approach that
their best clinical judgment dictates.
UNDERSTANDING WHO WILL DO BEST AND
WHO WILL NOT DO AS WELL
This complicated choice between multi-agent chemo-
therapy versus single-agent chemotherapy versus any chemo-
therapy at all has given rise to an emerging mandate in
geriatric oncology to identify tools to predict outcomes. Such
tools would be invaluable in helping patients and oncologists
to make cancer treatment decisions.
One recently published example of a major effort un-
dertaken to explore such prediction tools comes from the
several hundred-patient MILES study.14 This study formed
the platform from which a variety of prognostic factors
among older patients with lung cancer were assessed. It is a
particularly noteworthy example because it represents one of
the more robust, prospective efforts for tool validation. Eval-
uating baseline comorbidities, quality of life, activities of
daily living, and instrumental activities of daily living (ob-
tained from a very specific questionnaire) in 566 patients,
Maione et al.19 observed that quality of life and instrumental
activities of daily living had prognostic significance. Those
patients with better scores relevant to these variables did
better with cancer therapy. Of note, extent of comorbidities
did not carry this same prognostic effect. Such information is
critical in providing guidance for selecting the optimal cancer
therapy for a specific older patient with cancer. Results such
as these emphasize the importance of integrating such trans-
lational components into clinical trials and raise the possibil-
ity of including even laboratory-based efforts to improve our
understanding of prognosticators.
Recent recommendations from expert panels have em-
phasized the importance of defining subgroups of older pa-
tients with cancer based on their likelihood of doing well or
doing poorly after the administration of chemotherapy, and
the study by Maione et al.19 is an important example of using
this approach in a data-driven manner. A “comprehensive
geriatric assessment” has been discussed as an important first
step in evaluating any older patient with lung cancer,20 and an
example of this approach is shown in Figure 3. Using a
validated estimation of life expectancy, safety enhancements
that range from improving social support to using growth
factor support, and greater assurance of the patient’s desire to
receive chemotherapy, are important to consider as patients
and oncologists work together to design a cancer treatment
program.21–24 Some of these factors, such as comorbidity and
activity level, do have promise as predictors of outcome in
preliminary clinical investigations.25–27
At times, however, the role of a comprehensive geriat-
ric assessment and all such supplemental aspects of this
approach epitomize the great divide between medical oncolo-
gists and geriatricians (Figure 4). Geriatricians describe the
value of such tools in other clinical settings, but medical
oncologists find that time constraints and lack of clear direc-
tion on how to interpret findings make this approach subop-
timal. This area of developing practical, accurate, and clini-
cally relevant prognostic tools for older patients with lung
cancer promises to be one of tremendous growth in the future.
Such tools are needed to help oncologists to decide objec-
tively what sort of cancer treatment is most appropriate for a
given geriatric patient.
One final issue is the pitfall of oversimplifying the
administration of chemotherapy and of painting the decision-
making as only black and white. The importance of support-
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ive care, such as the use of growth factor support to lessen the
prevalent problem of myelosuppression, calls attention to the
availability of mitigating therapies that can make chemother-
apy easier for the older cancer patient. For example, the
NCCN Guidelines state,23,28 “The prophylactic use of hema-
topoietic growth factors in persons who are 65 years or older
is recommended for patients receiving CHOP or CHOP-like
chemotherapy in the treatment of lymphoma.” Although
many patients with metastatic non-small cell lung cancer are
unlikely to receive a regimen as myelosuppressive as
“CHOP” for their disease, the aggressive use of supportive
care in older patients with lung cancer should be readily
acknowledged and implemented.
WORKING TOWARD “DO NO HARM” WITH
CHEMOTHERAPY
Some oncologists may recruit older patients with lung
cancer to elderly-specific clinical trials with some degree of
trepidation. Do elderly-specific trials in effect under-treat
older patients with cancer and deprive them of the advantages
of chemotherapy? Do such trials even address the adverse
events observed in retrospective analyses of age-unrestricted
trials? The North Central Cancer Treatment Group recently
published a pooled analysis of its data in an attempt to answer
both these questions in a preliminary fashion.29 Baseline
characteristics and outcomes were directly compared within
older patients with non-small cell lung cancer who had
participated in elderly-specific trials and in age-unspecified
trials as first-line therapy for metastatic disease. Again, all
patients within the pooled analysis were 65 years of age or older,
but the difference between the two cohorts rested in the type of
trial in which they had participated: 118 were in the elderly-
specific trials, and 108 were in the age-unspecified trials.
There were several notable aspects of this analysis that
clearly justify the conduct of elderly-specific trials. First, the
age of patients in these studies was more advanced. For
example, the percentage of patients older than 80 years was
greater: 17% versus 3% (p  0.0008) (Figure 5). This
observation underscores the important role of elderly-specific
trials in embracing older patients with cancer into the cancer
clinical trial infrastructure. Second, median survival times
were comparable based on trial type, even after adjustment
for other prognostic factors: 232 days versus 302 days (p 
0.16). This finding suggests that patients are not deriving
compromised outcomes as a result of participation in elderly
trials. Third, and most notably, adverse events were worse in
the age-unspecified trials. Grade 3 or worse non-hematolog-
ical toxicity occurred in 81% versus 57% of patients in
age-unspecified versus age-specific trials, respectively (p 
0.001). Grade 3 or worse hematologic adverse events oc-
curred in 68% versus 10%, respectively (p 0.001). It seems
that preliminarily elderly-specific trials were not causing
FIGURE 3. Geriatricians and medical oncologists sometimes differ in the value placed on the comprehensive geriatric assess-
ment. Succinct tools with greater prognostic accuracy are likely to play an important role in clinical practice once they have
been developed and validated, as hypothesized above.
FIGURE 4. Comprehensive geriatric assessment: The Great
Divide between Medical Oncologists and Geriatricians?
Jatoi and Aranguren Journal of Thoracic Oncology • Volume 2, Number 1, January 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer88
undue suffering in patients with metastatic non-small cell
lung cancer.
In summary, the above findings suggest that older
patients with non-small cell lung cancer who participate in
elderly-specific trials suffer lower rates of severe adverse
events with comparable survival. At the same time, such trials
include the “oldest of the old” into the cancer clinical trial
infrastructure. The foregoing data are considered highly pre-
liminary, but they nonetheless provide some justification for
the future development and implementation of clinical trials
in older patients with lung cancer.
AN OVERVIEW OF ONGOING TRIALS
If one examines a current list of all the 295 ongoing
trials in non-small cell lung cancer, as listed on the PDQ
Database as of April 2006, three notable points emerge,
particularly as they relate to older patients with lung cancer.
Of note, the PDQ Database attempts to list all trials regardless
of funding source or country of origin. Admittedly, such a
daunting task is likely to result in the inadvertent omission of
some trials. Nonetheless, much can be learned. First, many of
the listed trials have an upper age limit that specifically and
intentionally excludes older patients with lung cancer. Of
these studies, 28 provide an upper age restriction of 50 to120
years; most excluded patients at the age of 70 or 75 years and
all patients older than that. Indeed, the number of elderly-
specific trials that restrict eligibility exclusively to older
patients with cancer consists of only eight trials, which is
markedly lower than the number that intentionally excludes
older patients. If for no other reason, elderly-specific trials
should be encouraged to compensate for the number of trials
that intentionally exclude older patients with cancer.
Second, there seems to be a shortage of innovation. One
interesting phase II trial tests vinorelbine and bevacizumab,
and another tests cetuximab and vinorelbine. However, these
two studies are the only ones that test relatively new agents.
Many of the newer drugs available for treating non-small cell
lung cancer have more acceptable adverse event profiles;
therefore, one might justify the testing of novel agents in
elderly-specific trials. Perhaps even single-agent, first-line
studies could be justified among older patients with cancer,
especially given the phase III data that have yielded favorable
results with single-agent therapy.
Third, there is a dearth of phase III studies available to
older patients with cancer. Presently, only four such studies
are open, and none of these are widely available in the United
States. There is a need to conduct more phase III trials that
promise to shed light on the best treatment approaches for
geriatric patients with lung cancer. Indeed, the major conclu-
sions of this review, such as the role of chemotherapy in
prolonging survival in older patients with non-small cell lung
cancer and the justification for prescribing single-agent ther-
apy to some older non-small cell lung patients with cancer,
were formulated only as a result of such large phase III
studies.
CONCLUSION
Today, relatively few elderly-specific cancer chemo-
therapy trials are ongoing in the United States, and relatively
few studies even seem to include planned subgroup analyses
based on age. Yet the number of geriatric patients with lung
cancer is increasing, new chemotherapy drugs are emerging,
and the need for rigorous evidence-based guidance in man-
aging these patients is perhaps as great as it has ever been.
Although the fundamental role of chemotherapy in treating
select older patients with non-small cell lung cancer has been
established, further research in this field promises to provide
a major favorable impact on patient care.
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